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Activation of the nuclear factor jB/c-Rel can increase neuronal resilience to pathological noxae by regulating the expression
of pro-survival manganese superoxide dismutase (MnSOD, now known as SOD2) and Bcl-xL genes. We show here that
c-Rel-deficient (c-rel/) mice developed a Parkinson’s disease-like neuropathology with ageing. At 18 months of age,
c-rel/ mice exhibited a significant loss of dopaminergic neurons in the substantia nigra pars compacta, as assessed by
tyrosine hydroxylase-immunoreactivity and Nissl staining. Nigral degeneration was accompanied by a significant loss of dopa-
minergic terminals and a significant reduction of dopamine and homovanillic acid levels in the striatum. Mice deficient of the
c-Rel factor exhibited a marked immunoreactivity for fibrillary a-synuclein in the substantia nigra pars compacta as well as
increased expression of divalent metal transporter 1 (DMT1) and iron staining in both the substantia nigra pars compacta and
striatum. Aged c-rel/ mouse brain were characterized by increased microglial reactivity in the basal ganglia, but no astrocytic
reaction. In addition, c-rel/ mice showed age-dependent deficits in locomotor and total activity and various gait-related
deficits during a catwalk analysis that were reminiscent of bradykinesia and muscle rigidity. Both locomotor and gait-related
deficits recovered in c-rel/ mice treated with L-3,4-dihydroxyphenylalanine. These data suggest that c-Rel may act as a
regulator of the substantia nigra pars compacta resilience to ageing and that aged c-rel/ mice may be a suitable model of
Parkinson’s disease.
Keywords: Parkinson’s disease; NFkB/c-Rel; -synuclein; motor impairments; L-DOPA
Abbreviations: ChAT = choline acetyl transferase; GFAP = glial fibrillary acidic protein; MPTP = 1-methyl-4-phenyl-1,2,3,
6-,tetrahydropyridine
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Parkinson’s disease is the most common neurodegenerative
movement disorder, with clinical symptoms that include resting
tremor, rigidity and bradykinesia (Fahn, 2003). The aetiology of
Parkinson’s disease is not well understood but it is likely that it
involves both genetic and environmental factors (Wirdefeldt et al.,
2011). The pathological hallmarks of Parkinson’s disease are the
loss of dopamine neurons in the pars compacta of the substantia
nigra and the accumulation of somatic and intraneuritic inclusions,
which are mainly composed of filamentous -synuclein aggregates
called Lewy bodies and Lewy neurites, respectively (Spillantini
et al., 1998; Bellucci et al., in press). Furthermore, the activation
of microglia and neuroinflammatory changes (Hirsch and Hunot,
2009), accumulation of iron with its transporter, the divalent metal
transporter 1 (DMT1) (Salazar et al., 2008), are found in the
Parkinson’s disease brain.
In post-mortem Parkinson’s disease brains, affected dopamin-
ergic neurons display morphological characteristics of apoptosis,
including cell shrinkage, chromatin condensation and DNA frag-
mentation (Olanow and Tatton, 1999; Dauer and Przedborski,
2003). To date, the mechanisms underlying the progressive loss
of dopamine neurons in Parkinson’s disease remain unknown.
NFkB is a cardinal transcriptional regulator of inflammation and
apoptosis that can contribute to the pathological processes asso-
ciated with neurodegeneration (Pizzi and Spano, 2006; Camandola
and Mattson, 2007). NFkB is activated in the neurons of brains
exposed to trauma or ischaemia (Bethea et al., 1998; Schneider
et al., 1999), as well as in the brains of patients affected by
Parkinson’s disease (Hunot et al., 1997; Ghosh et al., 2007) and
Alzheimer’s disease (Kaltschmidt et al., 1997). Of note, conflicting
evidence has emerged regarding the pro-apoptotic or anti-
apoptotic pathway activated by NFkB in neurons (Pizzi and
Spano, 2006; Camandola and Mattson, 2007). We recently
showed that the subunit composition of the NFkB dimer is essen-
tial to define the pro- or anti-apoptotic activity of this factor. Five
DNA-binding proteins [p50, p52, p65 (RelA), c-Rel and RelB] can
compose the NFkB complexes, and targeting RelA or c-Rel expres-
sion revealed opposing regulation of neuron survival. The RelA
subunit within the activated p50/RelA dimer plays a pivotal role
in the onset of neurodegenerative processes triggered by ischae-
mic insults or glutamate and amyloid-b toxicity (Pizzi et al., 2002,
2005; Inta et al., 2006) and activates the transcription of
pro-apoptotic Bim (now known as Bcl2l11) and Noxa (now
known as Pmaip1) genes (Inta et al., 2006). Conversely, the
c-Rel subunit within activated NFkB dimer counteracts the ischae-
mic injury (Sarnico et al., 2009) and is responsible for neuropro-
tection elicited by IL1b, mGlu5 agonists or leptin (Pizzi et al.,
2002, 2005; Valerio et al., 2009). Over-expression of c-Rel in
cultured neurons promotes anti-apoptotic effects by inducing the
transcription of manganese superoxide dismutase (MnSOD, now
known as SOD2) and Bcl-xL (Chen et al., 2000; Bernard et al.,
2001; Pizzi et al., 2005; Sarnico et al., 2009). Over-expression
of c-Rel also limits the generation of reactive oxygen species by
inducing transcription of the mitochondrial uncoupling proteins
4 (UCP4) (Ho et al., 2012), a brain-specific mitochondrial ion
channel producing mild reduction of mitochondrial membrane po-
tential and neuroprotection (Echtay, 2007). Knocking down c-Rel
expression with RNA interference suppresses the pro-survival
effects of NFkB and increases neuronal susceptibility to brain is-
chaemia (Sarnico et al., 2009). This evidence, in addition to the
demonstration that c-rel/ mice display deficits in spatial
memory formation, long-term potentiation and long-term depres-
sion of hippocampal synaptic transmission (Levenson et al., 2004;
O’Riordan et al., 2006; Ahn et al., 2008), indicates a peculiar role
for c-Rel in the regulation of fundamental brain functions, such as
resilience to stressful conditions and cognition.
In this study, our working hypothesis was that the c-Rel protein
might play a role in neurological conditions associated with neur-
onal cell loss and that changes in c-Rel expression might contrib-
ute to neuronal vulnerability in age-related neurodegeneration. In
line with this hypothesis, we investigated the occurrence of patho-
logical changes in c-rel-deficient mice that may be associated with
changes occurring in Parkinson’s disease. We found that aged
c-rel/ mice developed Parkinson’s disease-like degeneration of
substantia nigra pars compacta characterized by a loss of dopa-
minergic neurons, increased levels of iron and DMT1, as well as an
accumulation of aggregated -synuclein with activation of micro-
glial cells. In addition, c-rel/ mice showed motor deficits similar
to Parkinson’s disease-like hypokinesia, suggesting that they may
represent a valuable model of parkinsonism.
Materials and methods
Experimental animals
C57BL/6 mice carrying the c-Rel gene null mutation (c-rel/) were
originally generated by inserting the neomycin cassette into the fifth
exon of the c-Rel gene (Liou et al., 1999). The c-rel/ mice were
backcrossed to C57BL/6 J mice for nine generations before being used
in this study. The genotypes were verified by PCR analysis (wild-type
c-rel forward primer, 50-AAGTGGGGTTACAGGTGCTCA-30; wild-type
c-rel reverse primer, 50-TTGCCAATAGGCTTAGTCAAATA-30; c-rel
neomycin reverse primer, 50-CTCTCGTGGGATCATTGTTTTTC-30).
PCR conditions were 94C for 30 s, 57C for 30 s, 72 for 30 s (30
cycles). The c-rel/ and c-rel + / + (wild-type) lines were continued by
homozygous breeding. Animals were housed in standard cages and
maintained under a 12h/12h light:dark cycle with food and water
available ad libitum. Humidity was kept at a constant level, and the
room temperature was maintained at 22–23C. All animal experiments
were authorized by the Italian Ministry of Health and by the University
of Brescia Animal Care Committee in compliance with the Italian
guidelines for animal care (DL 116/92) and the European
Communities Council Directive (86/609/EEC).
Immunohistochemistry
Mice were anaesthetized with chloral hydrate (400 mg/kg intraperito-
neally) and transcardially perfused with PBS (SIGMA), 4% (w/v)
ice-cold paraformaldehyde and 14% (w/v) ice-cold picric acid
(SIGMA). Coronal slices (30 or 10 mm thickness) were cut to obtain
serial sections of the following cerebral areas using bregma-based co-
ordinates (Franklin and Paxinos, 2008): substantia nigra pars compacta
(anterior–posterior 2.54 to 3.40 mm), ventral tegmental area
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(anterior–posterior 2.92 to 3.80 mm), medial septal area (anterior–
posterior 1.18 to 0.38 mm), nucleus basalis magnocellularis (anterior–
posterior 0.34 to 1.34 mm) and striatum (anterior–posterior 1.70
to 2.30 mm).
3,30-Diaminobenzidene immunostaining was performed on free-
floating sections (30 mm) using primary antibodies: rabbit polyclonal
anti-tyrosine hydroxylase (1:400 Millipore); polyclonal anti-choline
acetyl transferase (ChAT; 1:500 Chemicon); mouse monoclonal
anti-neuronal nuclei antibody (NeuN; clone A60, 1:100 Millipore);
anti--synuclein antibody (Syn-1, 1:500 BD); monoclonal mouse
anti-glial fibrillary acidic protein (GFAP; 1:400, Sigma); monoclonal
rat anti-mouse CD11b (1:1000, Serotec). Brain sections were incu-
bated in biotinylated secondary antibodies (all purchased from
Vector) and visualized by avidin–biotin–horseradish peroxidase tech-
nique (ABC Elite; Vector Laboratories) using 0.025% 3,30-diaminoben-
zidine (Sigma) as the chromogen. NeuN staining was intensified by
adding 0.02% NiCl2 to 3,3
0-diaminobenzidine solution.
The double tyrosine hydroxylase staining was performed by incubat-
ing the sections previously processed for -synuclein immunoreactivity
in the anti-tyrosine hydroxylase antibody and biotinylated secondary
antibody (goat anti-rabbit 1:250 Dako) followed by the avidin–biotin–
horseradish peroxidase complex and SG reagent as chromogen.
For ferric iron, a Prussian blue stain with diaminobenzidine enhance-
ment was used (Smith et al., 1997). Sections were incubated with 7%
potassium ferrocyanide (Perls reagent) in 3% HCl for 1 h at 37C
followed by distilled water and 0.015% H2O2-activated 0.75 mg/ml
diaminobenzidine in 0.1 M PBS for 10 min.
Nissl staining of substantia nigra pars compacta was performed by
incubating the sections (10-mm thick) in 0.5% cresyl violet
(Sigma-Aldrich). Sections were dehydrated and defatted in xylene
and mounted with Eukitt (Calibrated Instruments).
Double immunofluorescence staining was performed in sections
(10 mm) incubated with -synuclein antibody overnight at 4C fol-
lowed by a goat anti-mouse secondary antibody conjugated with
Cy3 (1:400 Jackson ImmunoResearch) for 30 min at room tempera-
ture. Slices were then incubated with a primary rabbit anti-tyrosine
hydroxylase (1:200 Chemicon) antibody overnight at 4C followed
by incubation in Alexa Fluor 405-conjugated secondary antibodies
(1:400 Jackson ImmunoResearch). For thioflavin S/-synuclein
double staining, sections were incubated with 0.3% KMnO4 for
3–5 min, washed with water and incubated with a solution of 0.1%
NaBH4 for 5 min and then placed in a high-concentration PO4 buffer
(411 mM NaCl, 8.1 mM KCl, 30 mM NaHPO4, 5.2 mM KH2PO4) pH
7.2. After washing, thioflavin S (Sigma-Aldrich) and -synuclein immu-
nostaining was performed and the sections examined with a Zeiss,
LSM 510 META confocal microscope (Carl Zeiss), with the laser set
at  = 405–488–543 nm and the height of the section scan-
ning = 1 mm. Images (512  512 pixels) were then re-constructed
using LSM Image Examiner (Carl Zeiss) and Adobe Photoshop 7.0
software.
Cell quantification
The number of tyrosine hydroxylase-, ChAT- and NeuN- immunopo-
sitive or Nissl-stained cells was stereologically estimated by double-
blind cell counting in bright field microscopy using an optical fractio-
nator method (King et al., 2002). Neurons from the substantia nigra
pars compacta, ventral tegmental area, basal forebrain and striatum
were analysed with an inverted microscope (Zeiss Axiovert S100 and
camera PCO Sensicam) interfaced with a PC running the StagePro
module of Image-ProTM Plus software (version 6.2, Media
Cybernetics, Inc.) as previously described (King et al., 2002). The
entire extension of mesencephalon, basal forebrain and striatum
were cut into sections. Three sections (30 mm thick) were examined
every 150mm in a rostro-caudal extension. In the mesencephalon,
tyrosine hydroxylase-immunoreactive cells lateral to the medial ter-
minal nucleus of the accessory optic tract, which defines the medial
border of the substantia nigra pars compacta were counted. The ven-
tral tegmental area was thereby excluded from these cell counts.
Tyrosine hydroxylase-positive cells in the ventral tegmental area
were counted in a separate analysis. Nissl-stained neurons in the
substantia nigra were examined in two sections (10mm thick) every
150 mm.
The number of cholinergic neurons in the basal forebrain was deter-
mined by counting ChAT-positive cells in the medial septal area and in
the nucleus basalis magnocellularis. For the striatum, NeuN-positive
cells with identifiable nuclei were counted in three regions selected
between lateral 1.00 to 2.00 mm and ventral 2.00 to
3.00 mm, (520  380 mm; left and right). Values are expressed as
the mean  SEM.
The optical density of striatal tyrosine hydroxylase-positive fibres
was examined from digitized images using Image-Pro Plus software
(version 6.2, Media Cybernetics). Brains from four mice (three sections
from each mouse) were analysed by examining an average of 10 fields
per section.
Quantification of CD11b- and glial
fibrillary acidic protein-positive cells
Quantification of CD11b and GFAP immunostaining was carried out in
brain slices sections processed on the same day in order to avoid any
difference in staining intensity among animals. All pictures were cap-
tured within the same session in order to avoid any difference in any
differences in lighting conditions. In each section, the entire left and
right substantia nigra pars compacta were analysed, whereas for the
striatum evaluation, one portion from the dorsolateral striatum (lateral
from 1.65 to 2.15; ventral from 2.00 to 2.40) and one from
the ventromedial striatum (lateral from 1.25 to 1.75; ventral from
1.75 to 2.15, 520  380mm; left and right) were analysed. For
each animal, three sections from the substantia nigra pars compacta
(anterior–posterior 2.92 mm, 3.28 mm and 3.64 mm from
bregma, according to the mouse brain atlas by Franklin and Paxinos,
2008) and three sections from the striatum (anterior–posterior
1.10 mm, 0.74 mm and 0.38 mm from bregma) were analysed.
CD11b immunostaining was evaluated with the Scion Image analysis
program (Scion Corp.). Inside each frame, the area occupied by grey
values above the threshold was automatically calculated. For each level
of the substantia nigra pars compacta or striatum the obtained value
was first normalized with respect to vehicle, and the values from the
different levels were then averaged. For GFAP analysis, in the sub-
stantia nigra pars compacta and striatum, the mean number of
GFAP-positive cells obtained from each experimental group was first
normalized with respect to vehicle and the values from the different
levels were then averaged.
a-Synuclein extraction
Twenty milligrams of brain tissue were homogenized in five volumes
of Tris-buffered saline plus (TBS + ) buffer (Tris–HCl 50 mM pH 7.4,
NaCl 175 mM, EDTA 5 mM, PMSF 0.1 mM and N-ethylmaleimide
1 mM; Sigma) using a glass homogenizer on ice. The homogenate
was centrifuged at 120 000 g for 30 min at 4C. The supernatant
(S1) was saved, and the pellet was dissolved in TBS + buffer with
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1% TritonTM X-100 and centrifuged at 120 000 g for 30 min at 4C to
obtain the second supernatant (S2). The procedure was repeated, the
supernatant (S3) was retained and the pellet was dissolved in urea 8 M
(SIGMA) with SDS 5% to obtain the supernatant S4.
Immunoblot analysis
To analyse the tissue level of soluble -synuclein, supernatants S1, S2
and S3 were loaded into SDS–PAGE gels and analysed by western blot
technique. S4 supernatants were analysed to detect insoluble
-synuclein. Briefly, protein extracts were diluted in loading buffer
(Sigma) and boiled for 2 min before being loaded into an SDS–PAGE
gel and transferred to a nitrocellulose membrane (Amersham).
Membranes were then incubated with either -synuclein (1:500; BD)
or monoclonal anti-b-actin (1:10 000; Sigma) primary antibody and
secondary antibodies coupled to horseradish peroxidase (1:1500,
Santa Cruz Biotechnology). Immunopositive bands were visualized by
enhanced chemiluminescence detection (ECL) reagents (Amersham).
DMT1 immunoreactivity was examined in total mesencephalic
and striatal extracts by using a pan-DMT1 antibody (Santa Cruz
Biotechnology). The levels of dopamine transporter were analysed in
striatal extracts using the anti-dopamine transporter rat monoclonal
antibody (Santa Cruz Biotechnology 1:200). Gel analysis was per-




Striatal tissue was sonicated in 250ml of 0.2 M perchloric acid and
centrifuged at 11 000 g for 15 min at 4C. The supernatant was filtered
(0.45 mm) and diluted 1:62.5. Twenty microlitres were injected into an
HPLC with a reverse-phase column [LC-18 DB, 15 cm, 5-mm particle
size and a coulometric detector (ESA Coulochem II)] to quantify mono-
amines and their metabolites. For dopamine and noradrenaline (NA),
the mobile phase was: NaH2PO4, 100 mM; Na2EDTA, 0.1 mM; N-octyl
sodium sulphate, 0.5 mM; 7.5% methanol; pH 5.5. For 5-hydroxy-
tryptamine, 5-hydroxyindoleacetic acid, dihydroxylphenylacetic acid
and homovanillic acid, the mobile phase was: CH3COONa, 0.23 M;
citric acid, 0.15 M; Na2EDTA, 100 mg/ml; 6.5% methanol; pH: 4.7.
The sensitivity of the assay was 10 fmol/sample. The values of these
monoamines are expressed as picomoles/gram wet weight of tissue.
Behavioural studies
Motor activity assessment
Spontaneous motility was assessed in a quiet isolated room. Mice were
placed individually in plexiglass cages (length 47 cm, height 19 cm,
width 27 cm) with a metal grid over the floor and equipped with in-
frared photocell emitters-detectors situated along the long axis of each
cage (Opto-Varimex Mini; Columbus Instruments). The interruption of
a photocell beam was detected by a counter that recorded the total
number of photocell beam interruptions. The counter recorded two
different types of motor activity: locomotor activity due to the loco-
motion of the mouse along the axes of the cage and total motor
activity due to locomotion plus non-finalized movements (stereotyped
behaviours such as grooming, rearing, and sniffing). The counter
recognized the stereotyped movements because of the continuous
interruption of the same photocell beam, whereas locomotion along
the cage produced interruptions of different photocell beams. Motor
activity counts were evaluated for 60 min. Spontaneous locomotor
activity was further investigated and expressed as distance travelled
by using an automated video tracking system (EthoVision XT, Noldus
Information Technology) in a 45  45 cm cage, with walls of clear
acrylic poly(methyl methacrylate) (Phenotyper mod. 4500, Noldus).
On this occasion, PhenoTyper was used as a basic cage for a short
period of time (1 h). Locomotor activity was also evaluated using the
PhenoTyper home cages (Noldus Information Technology) under a
reversed light:dark cycle (white light: 20:00–8:00 h, red light:
8:00–20:00 h), with food and water available ad libitum. One
animal per cage was analysed for six consecutive days with 24 h of
automated monitoring. The principal parameter analysed was the total
distance moved (cm) in a day.
CatWalk gait analysis
Gait parameters were evaluated using the CatWalk 7.1 system
(Noldus). All data analyses were performed with a pixel threshold
value 525 arbitrary units. Mice were subjected to 3 days of training
before the test. Mice were trained to cross the walkway (30 min/day)
and were rewarded after every successful continuous run with highly
palatable food. Animals were subjected to a food restriction protocol
consisting of a diet of 1.5 g/day of standard laboratory chow. Water
was available ad libitum. Testing was performed on Day 4 when the
animals completed three runs without hesitation, and parameters such
as base of support, print length, maximum contact at (%) and swing
speed were measured. The weight of the animals was monitored
during all the experiments.
L-DOPA treatment
L-DOPA (L-3,4-dihydroxyphenylalanine methyl ester hydrochloride)
and benserazide hydrochloride were purchased from Sigma Aldrich
and freshly dissolved in a saline solution at a final injection volume
of 5 ml/kg. Both L-DOPA (20 mg/kg) and benserazide hydrochloride
(12.5 mg/kg) or vehicle (saline) were injected intraperitoneally into
mice 1 h before the beginning of the behavioural tests.
Locomotor activity was individually measured as described above.
Briefly, the animals were singularly placed in a novel PhenoTyper cage
and spontaneous locomotor activity was video-recorded. Videos were
then analysed by Ethovision XT software. For the CatWalk gait ana-
lysis, trained mice were treated with L-DOPA and tested as described
above.
Statistical analysis
Statistical analysis was performed with the GraphPad Prism 4.0 pro-
gram. Comparisons between two groups were performed using the
two-tailed unpaired Student’s t-test. Data were expressed as the
mean  SEM. Statistical significance was accepted at the 95% confi-
dence level (P5 0.05).
The variations in monoamines and their metabolites were evaluated
by a one-way ANOVA followed by Tukey’s post hoc test.
Motor activity was evaluated using a one-way ANOVA followed by
the Newman-Keuls post hoc test. Performance in the PhenoTyper
cages was evaluated with a two-tailed unpaired Student’s t-test.
Statistical significance was accepted at the 95% confidence level
(P5 0.05). For the analysis of gait parameters, the means of the
hind and front paws were considered. The individual averages for
each mouse were calculated over three runs, and the differences be-
tween groups were evaluated with a two-tailed unpaired Student’s
t-test. Statistical significance was accepted at the 95% confidence
level (P5 0.05).
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Dopaminergic neuronal loss in the
substantia nigra pars compacta of
18-month-old c-rel/ mice
We studied possible occurrence of age-related neurodegeneration
in the substantia nigra pars compacta of c-rel/ mice.
The quantification of substantia nigra pars compacta dopamin-
ergic cell bodies and their projecting fibres in the striatum was
performed using tyrosine hydroxylase immunostaining. Our results
showed a significant loss of dopaminergic neurons in the substan-
tia nigra pars compacta of c-rel/ mice with ageing. Indeed,
18-month-old mice displayed a 40% reduction in dopaminergic
neurons compared with wild-type mice (c-rel/ 4671  239,
wild-type 7569  316; P50.05; Fig. 1G–I). No decrease in dopa-
minergic neurons was detected in 2-month-old c-rel/ mice
(Fig. 1A–C) (c-rel/ 7289  322, wild-type 6905  380;
P4 0.05) or 12-month-old animals (Fig. 1D–F) (c-rel/
7801  407, wild-type 7720  395; P40.05). Remarkably, the
loss of tyrosine hydroxylase-positive neurons in 18-month-old
c-rel/ mice paralleled the total loss of Nissl-stained cells
(c-rel/ 9809  558, wild-type 13397  620; P50.05) in the
substantia nigra pars compacta, suggesting that dopaminergic
neuron survival and not simply tyrosine hydroxylase expression
was diminished in the brains of aged c-rel/ mice (Fig. 1L–N).
No significant change in the estimated number of Nissl-stained
cells was evident in the substantia nigra pars compacta of
2- and 12-month-old c-rel/ mice compared with age-matched
controls (data not shown).
Neurons of ventral tegmental area,
medial septal area, nucleus basalis
magnocellularis and striatum are
spared from degeneration in aged
c-rel/ mice
With the aim to investigate other brain regions possibly undergo-
ing age-related degeneration, we evaluated the survival of dopa-
minergic neurons in the ventral tegmental area and of cholinergic
Figure 1 Age-dependent loss of dopaminergic neurons in the substantia nigra of c-rel/ mice. Representative pictures of tyrosine
hydroxylase staining in the substantia nigra dopaminergic neurons of wild-type and c-rel/ mice at 2 months (A and B), 12 months
(D and E) and 18 months (G and H). The data from stereology analysis of tyrosine hydroxylase-positive cells are shown in C, F and I.
A significant decrease of the number of tyrosine hydroxylase-positive neurons was detected in 18-month-old c-rel/ mice. The data
represent the means  SEM (n = 8 mice/group, *P50.05 versus wild-type mice). Representative pictures of Nissl staining in the
substantia nigra of 18-month-old wild-type (L) and c-rel/ mice (M) confirmed the loss of neurons. Data from stereology analysis
are reported in N. Scale bar in B = 350mm and applies to A–M. TH = tyrosine hydroxylase.
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cells in the medial septal area and nucleus basalis magnocellularis.
No change in the number of tyrosine hydroxylase-positive neurons
in the ventral tegmental area of c-rel/ mice was detected either
at 2 (data not shown) or 18 months (Fig. 2A–C). Likewise, no
significant difference in the ChAT-positive cholinergic neurons
was found in the medial septal area (Fig. 2D–F) and the nucleus
basalis magnocellularis (Fig. 2G–I) of c-rel/ mice at 18 months
or 2 months (data not shown). We also evaluated a possible loss
of striatal neurons in c-rel/ mice. No difference in the estimated
number of NeuN-positive neurons was detected in 18-month-old
(Fig. 2L–N) and 2-month-old (data not shown) c-rel/ mice.
Loss of dopaminergic terminals in the
striatum
To determine whether the loss of dopaminergic neurons in the
substantia nigra pars compacta of c-rel/ mice was associated
with a reduction in the number of nigrostriatal projections,
we quantified tyrosine hydroxylase-positive nerve terminals in
the dorsal striatum. Our experiments showed a reduction of
50% of the area occupied by tyrosine hydroxylase-positive
fibres in the striatum of 18-month-old c-rel/ mice (Fig.
3A–E).
As a marker of dopaminergic terminals, we also evaluated stri-
atal dopamine transporter levels in 18-month-old control and
knockout mice. In parallel with the loss of tyrosine hydroxylase-
positive fibres, western blot analysis (Fig. 3F) showed a marked
decrease in dopamine transporter immunoreactivity in c-rel/
mice with respect to wild-type mice. To corroborate the dopamin-
ergic terminal loss in the striatum of 18-month-old c-rel/ mice
we investigated the occurrence of neurochemical changes by mea-
suring dopamine and dopamine metabolites in whole striata using
HPLC (Fig. 3G). Dopamine and homovanillic acid levels appeared
significantly decreased in c-rel/ mice when compared with
Figure 2 Tyrosine hydroxylase staining in the ventral tegmental area, ChAT staining in the medial septal area and nucleus basalis
magnocellularis, NeuN staining in the striatum, of 18-month-old mice. Representative photomicrographs of tyrosine hydroxylase staining
in the ventral tegmental area of wild-type (A) and c-rel/ (B) mice. (C) Densitometry analysis of tyrosine hydroxylase-positive cells. No
significant decrease in tyrosine hydroxylase-positive neurons was evident in c-rel/ mice. The data represent the mean  SEM (n = 7
animals per group, *P50.05 versus wild-type mice). Representative photomicrographs are shown of ChAT staining in the medial septal
area of wild-type (D) and c-rel/ mice (E) and in the nucleus basalis magnocellularis of wild-type (G) and c-rel/ (H) animals.
Representative pictures of NeuN staining in the striatum of wild-type (L) and c-rel/ (M) mice. No significant difference in the estimated
number of ChAT-positive cells in the medial septal area (F) and the nucleus basalis magnocellularis (I) or NeuN-positive neurons in the
striatum (N) was evident between the two groups. Data represent the means  SEM (n = 6 animals per group, *P50.05 versus wild-type
mice). Scale bars: in A = 350mm for A and B; in D = 500 mm for D and E; in G = 350 mm for G and H; L = 1200mm for L–M, l
insert = 300 mm for l, m. MSA = medial septal area; NBM = nucleus basalis magnocellularis; STR = striatum; VTA = ventral tegmental area;
wt = wild-type.
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wild-type animals, whereas dihydroxylphenylacetic acid levels
were unchanged. The dihydroxylphenylacetic acid:dopamine
ratio displayed a trend to increase that did not reach statistical
significance (data not shown), indicating that only a minor
up-regulation of dopamine turnover can occur in the nigro-striatal
terminals of aged c-rel/ mice. No significant difference in the
levels of noradrenaline, 5-hydroxytryptamine and its metabolite
5-hydroxyindoleacetic acid was evident between wild-type and
c-rel/ mice.
Accumulation of soluble and aggregated
a-synuclein and increase of DMT1 level
in the mesencephalon of 18-month-old
c-rel/ mice
After identifying dopaminergic neuronal loss in substantia nigra
pars compacta of c-rel/ mice at 18 months, we evaluated
specific markers associated with Parkinson’s disease at this time
Figure 3 Molecular changes in the dorsal striatum. Low (A and B) and high magnification (C and D) of representative pictures of tyrosine
hydroxylase immunostaining in caudate putamen sections from 18-month-old wild-type (A–C) and c-rel/ mice (B–D). (E) Densitometric
analysis revealed a significant decrease in the density of tyrosine hydroxylase-positive fibres in 18-month-old c-rel/ mice. The data
represent the mean  SEM (n = 4 animals per group, *P50.05 versus wild-type mice). Scale bar in A = 500mm for A and B; in
C = 300mm for C and D. (F) Representative immunoblotting of the dopamine transporter in the caudate putamen extracts of
18-month-old wild-type and c-rel/ mice. Densitometry analysis showed a significant reduction in dopamine transporter levels in
c-rel/ when compared with wild-type animals. Results represent the mean  SEM (n = 4 animals per group, *P50.05 versus wild-type
mice). (G) Quantification of dopamine, dopamine metabolites (dihydroxylphenylacetic acid and homovanillic acid), NA,
5-hydroxytryptamine with relative metabolite (5-hydroxyindoleacetic acid) detected in caudate putamen extracts of 18-month-old mice
by HPLC analysis. A significant decrease of dopamine and homovanillic acid levels was detected in c-rel/ mice. Data are means  SEM
of three independent experiments (n = 5 animals for group. *P5 0.05 versus wild-type mice). Quantification of noradrenaline, dopamine
with its metabolites (homovanillic acid and dihydroxylphenylacetic acid) and 5-hydroxytryptamine with its metabolite
(5-hydroxyindoleacetic acid) detected in the caudate putamen extracts of 18-month-old mice by HPLC analysis. A significant decrease
in dopamine and homovanillic acid levels was detected in c-rel/ mice. Data represent the mean  SEM of three independent experi-
ments (n = 5 animals per group, *P50.05 versus wild-type mice). DA = dopamine; DAT = dopamine transporter;
DOPAC = dihydroxylphenylacetic acid; HVA = homovanillic acid; 5HT = 5-hydroxytryptamine; 5HIAA = 5-hydroxyindoleacetic acid;
NA = noradrenaline.
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point. Lewy bodies, eosinophilic inclusions mainly composed of
filamentous -synuclein aggregates, are among the typical patho-
logical hallmarks of Parkinson’s disease. Hence, we studied
whether c-rel/ mice might display pathological deposition of
-synuclein. We found that c-rel/ mice showed specific immu-
noreactivity for -synuclein with the degeneration of dopaminergic
neurons in the substantia nigra pars compacta. A strong
-synuclein immunoreactivity (brown staining) indicative of pro-
tein accumulation, was visible within tyrosine hydroxylase-positive
neurons (blue staining) of c-rel/ mice (Fig. 4B, D and inset d).
Conversely, a weak -synuclein immunoreactivity was present
within tyrosine hydroxylase-positive neurons of wild-type animals
(Fig. 4A, C and inset c). The -synuclein-positive inclusions in the
dopaminergic neurons of the substantia nigra pars compacta were
thioflavin S-positive (Fig. 4F, H and insets f and h), indicating that
-synuclein protein was aggregated in a pathological fibrillary form
in c-rel/ mice.
The content of -synuclein sequentially extracted from the mes-
encephalon, cortex, striatum and hippocampus of mice was eval-
uated by western blot analysis (Fig. 4M–O). These extractions
were sequentially carried out in TBS + , TBS + and 1% TritonTM
X-100, and RIPA buffer for the isolation of the soluble form of
-synuclein and in 8 M urea/5% SDS to collect the insoluble frac-
tion. We detected an accumulation of native -synuclein protein in
the mesencephalon of c-rel/ mice when compared with
wild-type animals, but no significant change in the protein content
of other brain regions (cortex, striatum and hippocampus)
(Fig. 4M). Levels of soluble -synuclein in the TBS + and TBS +
with 1% TritonTM X-100 fractions were quantified by densitomet-
ric analysis. A statistically significant increase of soluble -synuclein
Figure 4 Accumulation of -synuclein in 18-month-old c-rel/ and wild-type mice. (A and D) Representative photomicrographs
showing tyrosine hydroxylase (blue) and -synuclein (brown) double staining in the substantia nigra of 18-month-old wild-type (A and C)
and c-rel/ mice (B and D). Note that the increase of brown -synuclein staining in the c-rel/ mice (d) completely covered the blue
tyrosine hydroxylase immunoreactivity observed in wild-type mice (c). (E-L) Representative photomicrographs showing -synuclein (red),
thioflavin S (green) and tyrosine hydroxylase (blue) triple staining in the substatia nigra of c-rel/ (E–H) and wild-type (I–L) mice.
Note that the -synuclein-positive aggregates in the brain of c-rel/ mice were also thioflavin S immunopositive, as visualized in the
high-magnification squares in panels E–H. Scale bars: in A = 3 mm for A and B; in C = 750 mm for C and D; in insert c = 10 mm for c and d;
in E = 50 mm for E–L; in insert e = 10mm for e–h. Panels A–L are representative of three independent experiments (n = 3 animals per
group). (M) Representative western blot showing sequential -synuclein extraction from diverse brain areas in 18-month-old wild-type
and c-rel/ (-/-) mice. Recombinant -synuclein ( + ) solution was used as positive control. Note the increase in
-synuclein-immunopositive bands in the mesencephalon of c-rel/ mice when compared with wild-type animals, as well as the
-synuclein immunopositive band in the urea extracts from c-rel/ mice. (N) Densitometric analysis of -synuclein-immunopositive
bands in the TBS and TBS/Triton fractions. Note the significant increase of -synuclein in the mesencephalon of c-rel/ mice. Data
represent the mean  SEM (n = 3 animals per group, *P50.05 versus wild-type mice). (O) Representative western blot showing
the increase in the -synuclein immunoreactive bands in the urea + SDS fractions from the mesencephalon of c-rel/ mice. Similar
results were obtained in three separate experiments.
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levels was detected in the mesencephalon of c-rel/ mice when
compared with wild-type mice (Fig. 4N). Accumulation of insol-
uble -synuclein in the mesencephalon was confirmed by the pres-
ence of a 19-kDa -synuclein-immunopositive band in the urea/
SDS extracts of aged c-rel/ mice but not in wild-type animals
(Fig. 4M and O).
As a further indication of the occurrence of Parkinson’s
disease-like pathological changes in the substantia nigra pars com-
pacta of c-rel/ mice, we measured DMT1 levels and iron stain-
ing. Western blot analysis by anti-DMT1 antibody revealed a
significant increase of the differently glycosylated 60 and 90 kDa
DMT1 components in the mesencephalic extracts of 18-month-old
c-rel/ mice. An increase in the 90 kDa component was
detected in striatal extracts (Fig. 5G and H). Also, we found an
elevation of iron levels by diaminobenzidene-enhanced Perl stain-
ing in the substantia nigra pars compacta of 18-month-old
c-rel/ mice as compared with the wild-type animals. A greater
number of iron-positive cells were evident along the entire sub-
stantia nigra pars compacta formation (Fig. 5A–F).
Microglia activation in substantia nigra
pars compacta and striatum of
18-month-old c-rel/ mice
To assess whether the age-related degeneration of substantia
nigra pars compacta dopaminergic cells in c-rel/ mice is accom-
panied by glial activation as described in Parkinson’s disease brain
we investigated microglial and astroglial morphology in the sub-
stantia nigra pars compacta and striatum. Compared with
aged-matched wild-type animals, 18-month-old c-rel/ mice
displayed marked microglial activation, as revealed by CD11b
immunostaining in the striatum and substantia nigra pars
compacta (Fig. 6A–D). The presence of microglial activation
in the substantia nigra pars compacta and striatum of c-rel/
mice was confirmed by the quantification of the CD11b-
immunopositive area (Fig. 6E). Analysis of GFAP immunostaining
revealed the presence of protoplasmic astrocytes that remained
non-reactive in the substantia nigra pars compacta and striatum
of c-rel/ mice (Fig. 6F–L).
Figure 5 DMT1 immunoreactivity and iron staining in mesencephalon of 18-month-old c-rel/ and wild-type mice. Tyrosine hydro-
xylase staining (A and B) and diaminobenzidine enhanced Perl iron staining (C–F) in sections of 18-month-old wild-type (A, C and E) and
c-rel/ mice (B, D and F). Higher magnifications of Perl iron staining are in panels E and F. While the number of tyrosine
hydroxylase-positive neurons decreased, the iron staining significantly increased in the substantia nigra pars compacta and reticulata of
c-rel/ mice compared with wild-type mice. Representative immunoblotting of the ferrous iron transporter DMT1 in the striatal and
mesencephalic extracts of 18-month-old wild-type and c-rel/ mice (G). Densitometric analysis of DMT1 relative to GAPDH (H). DMT1
60 and 90 kDa bands significantly increased in the mesencephalon of c-rel/ mice (-/-) compared with wild-type animals. Significant
difference in the DMT1 90 kDa band was detected in the striatum. Values represent the mean  SEM (n = 3 animals per group, *P50.001
versus wild-type mice) (F). Scale bar in A = 600 mm for A–D; in E = 75 mm for E and F.
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Three separate groups of either c-rel/ or wild-type mice at 4, 12
and 18 months of age were tested for their spontaneous motor be-
haviour. Motor activity was evaluated as total activity and locomotor
activity during 60 min of observation in photobeam cages recording
the number of photocell beam interruptions. At 4 or 12 months of
age, no significant difference was found in the spontaneous motor
and locomotor activity between the two groups (Fig. 7A and B). In
contrast, at 18 months, both the total and the spontaneous loco-
motor activity appeared to be reduced in c-rel/ mice (Fig. 7C).
Locomotor activity was also evaluated in 1-h video-tracking obser-
vations of individual mice in PhenoTyper cages, allowing an accurate
determination of total distance moved. Our observations confirmed
that the total distance covered by c-rel/ mice was significantly
lower than that moved by wild-type mice (Fig. 7D). Locomotor per-
formance was then continuously monitored for 6 days in the
PhenoTyper, which allowed home-cage evaluation of locomotor ac-
tivity, unaffected by anxiety. The total distance moved on Days 5
and 6 was significantly lower for c-rel/ mice compared with the
wild-type group (Fig. 7E).
Wild-type and c-rel/ mice were tested for their spontan-
eous gait behaviour (Fig. 8). No significant differences in weight
were observed within or between the experimental groups. Gating
of c-rel/ mice was affected: in particular, c-rel/ mice displayed
a lower swing speed (limb velocity when the paw is not in contact
with the ground) (Fig. 8A) and a wider distance between left and
right front-paws or hind-paws (base of support) (Fig. 8B and C).
Furthermore, c-rel/ mice needed a longer time to reach the
max contact (per cent of time spent to reach the maximal paw/
floor contact area, relative to the total time spent in contact with
the floor; Fig. 8D) and displayed a lower forepaw print length (Fig.
8E) when compared with wild-type animals (Fig. 8F).
L-DOPA supplementation
reverses motor deficits
The effect of dopamine replacement was tested by treating
c-Rel-deficient mice with L-DOPA (20 mg/kg) combined with ben-
serazide hydrochloride (12.5 mg/kg) or vehicle, 1 h before the be-
ginning of the behavioural tests. The acute L-DOPA administration
Figure 6 CD11b and GFAP immunoreactivity in 18-month-old c-rel/ and wild-type mice. Pictures of the substantia nigra pars
compacta (A and B) and striatum (C and D) sections from 18-month-old wild-type (A and C) and c-rel/ mice (B and D) illustrating
CD11b microglial immunostaining. (E) The quantification of CD11b is expressed as a percentage of grey values. There was significant
microglial activation in both the striatum and the substantia nigra pars compacta of c-rel/ mice. Images of the substantia nigra pars
compacta (F and G) and striatum (H and I) sections from 18-month-old wild-type (F and H) and c-rel/ mice (G and I) showing GFAP
astroglial immunostaining. (L) The percentage of GFAP-positive cells. No evident changes in astroglial activation were found in c-rel/
mice. Scale bars: in A = 200mm for A–D; in C’ and F = 50 mm for A’–D’ and F–I. Data represent the mean  SEM (n = 5 animals per group,
*P5 0.05, **P50.005 versus wild-type mice). SNc = sunstantia nigra pars compacta.
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significantly reversed the hypomotility of c-rel/ mice. The dis-
tance moved by the L-DOPA treated group during a 1 h observa-
tion was twice longer than that moved by vehicle-treated mice
(Fig. 9A). L-DOPA administration did not significantly modify the
locomotor activity in wild-type mice (data not shown).
Furthermore, L-DOPA supplementation reversed most of the
deficits in the gait-related parameters in trained c-rel/ mice.
Swing speed significantly increased (Fig. 9B) while the bases of
support (Fig. 9C and D) and the time to maximal contact
(Fig. 9E) significantly decreased. The print length tended to in-
crease in mice treated with L-DOPA (Fig. 9E).
Discussion
This study shows that mice carrying a knockout of NFkB c-Rel
factor developed a Parkinson’s disease-like phenotype with
ageing that makes them a suitable model for this disorder.
Eighteen-month-old c-rel/ mice displayed a selective loss of
tyrosine hydroxylase-positive neurons in the substantia nigra pars
compacta with accumulation of aggregated -synuclein, iron with
DMT1 and reduced dopamine content in the striatum. Moreover,
they developed age-dependent deficits in motor performance that
were reversed by acute L-DOPA supplementation. Although a lot
of effort has been devoted to studying Parkinson’s disease patho-
physiology, the mechanisms underlying the onset and progression
of the disease are still unclear, largely due to the lack of animal
models that reproduce the origin and symptoms of Parkinsonian
syndromes. The widely used models based on the administration
of neurotoxins do not include any genetic predisposition. They
show a rapid degeneration of dopaminergic neurons that does
not reproduce the multifactorial, slow and progressive changes
occurring in human disease (Tieu, 2011). The toxin-based
models highly contributed to the development of palliative thera-
pies, though their use has not led to successful disease-modifying
therapies for Parkinson’s disease. Since a large panel of genes is
related to the onset of familial forms of Parkinson’s disease (Bekris
et al., 2010), several genetic models have been developed, though
they only partially recapitulate certain aspects of the disease
(Chesselet and Richter, 2011).
It has been hypothesized that brain trauma may represent a risk
factors for the development of Parkinson’s disease via the induc-
tion of apoptotic biochemical cascades (Mattson and Camandola,
2001; Hutson et al., 2011). Among the mechanisms that control
neuronal survival in neurodegenerative diseases, the activation of
NFkB transcription factors is one of the most prominent (Mattson
and Camandola, 2001). Interestingly, in patients with Parkinson’s
disease the proportion of substantia nigra pars compacta dopamin-
ergic neurons with immunoreactive RelA in their nuclei was found
to be 470-fold that in controls (Hunot et al., 1997). Sustained
RelA activation has been found in mesencephalic astrocytes and
microglial cells of patients with Parkinson’s disease and
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated
mice. Remarkably, treatment with the IkB kinase inhibitor,
Figure 7 Spontaneous motor and locomotor activity in c-rel/ and wild-type mice. (A–C) Mice were tested at 4 months (A, n = 9–10),
12 months (B, n = 17–18) and 18 months (C, n = 14–18). The data represent the mean  SEM of the total motor and locomotor activity
counts registered during the 60-min observation (*P50.05 versus wild-type mice). (D) Mice at 18 months were tested by a
video-tracking system in a open field arena for 1 h. c-rel/ mice were less active as assessed by the total distance moved (cm) (n = 6
animals per group, *P50.05 versus wild-type mice). (E) The wild-type and c-rel/ mice at 18 months were maintained in a PhenoTyper
cage and continuously monitored for six consecutive days. The total distance moved (cm) in a day increased after 4 days of observation in
the wild-type group but not in the c-rel/ group (n = 11 animals per group, *P50.05 versus wild-type mice).
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NEMO-binding domain peptide, inhibited RelA activation and
counteracted the onset of microgliosis and neurodegeneration in
mice exposed to MPTP (Ghosh et al., 2007). This would support
the hypothesis that the activation of NFkB RelA is a key event in
neurodegeneration (Pizzi et al., 2002, 2005; Inta et al., 2006;
Sarnico et al., 2009). Conversely, NFkB containing the c-rel sub-
unit has been shown to prevent neuronal apoptosis in experimen-
tal models of stroke and Alzheimer’s disease (Pizzi et al., 2002,
2005; Sarnico et al., 2009; Valerio et al., 2009) as well as in
models of 1-methyl-4-phenylpyridinium (MPP + )-induced neuro-
toxicity (Sarnico et al., 2008).
Our working hypothesis was that due to the altered balance
between RelA- and c-Rel-mediated effects on neuron vulnerabil-
ity, mice carrying a knockout of the c-rel gene might develop
pathological brain alterations. c-Rel/ mice had normal brain
development and conserved good health during their lifetime.
However, at 18 months of age, these mice exhibited a 40%
loss of dopaminergic neurons in the substantia nigra pars com-
pacta, as assessed by tyrosine hydroxylase-immunoreactivity and
Nissl staining. No degeneration of dopamine neurons was detected
in the ventral tegmental area, a dopaminergic region commonly
spared in Parkinson’s disease (Dauer and Przedborski, 2003).
Likewise, there was no evident loss of cholinergic neurons in the
nucleus basalis magnocellularis and medial septal area of the basal
forebrain or in striatal neurons.
Mice carrying the c-Rel deficiency developed a significant loss
of nigral dopaminergic terminals in the striatum, as shown by the
reduced density of tyrosine hydroxylase-positive fibres and a
lower dopamine transporter protein level. There was lower striatal
concentration of dopamine and homovanillic acid, but no changes
Figure 9 L-DOPA treatment ameliorates the motor deficits in c-rel/ mice (18 months). L-DOPA (20 mg/kg) and benserazide
hydrochloride (12.5 mg/kg), or vehicle, were administered to mice 1 h before the beginning of the behavioural tests. (A) L-DOPA
treatment increased the spontaneous locomotor activity evaluated as total distance moved (cm) in the open field during 1 h observation
(*P50.05 versus vehicle). L-DOPA supplementation improved the gaiting performance by increasing the swing speed (m/s) (B),
by reducing the base of support for both the front (C) and hind paws (D) and by reducing the percentage of time spent to reach
the maximum contact (E) (*P5 0.05 versus vehicle). L-DOPA treatment increased, though not significantly, the fore paw print length
(mm) (F). veh = vehicle. The data represent the meanSEM of three runs per animal (n = 6 animals per group).
Figure 8 CatWalk gait analysis of c-rel/ and wild-type mice.
The data represent the mean  SEM of three runs per animal
(n = 11 animals per group). (A) Lower swing speed (m/s) and
higher base of support for both the front (B) and hind (C) paws
was observed in c-rel/ mice (*P50.05 versus wild-type
mice). Higher percentage of time spent to reach the maximum
contact (D) of the front limbs was observed in c-rel/ mice
(**P50.001 versus wild-type mice). A lower print length of the
front paws (E) was observed in c-rel/ mice (*P50.05 versus
wild-type mice).
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in noradrenaline, 5-hydroxytryptamine or 5-hydroxyindoleacetic
acid levels, illustrating the selective degeneration of nigral
dopamine neurons in these mice. Interestingly, dihydroxylpheny-
lacetic acid did not significantly decrease. Dopamine is metabo-
lized to dihydroxylphenylacetic acid and 3-methoxytyramine
through monoamine oxidase and catechol-O-methyl transferase,
respectively, and both are converted to homovanillic acid, as final
metabolite (Elsworth and Roth, 1997). A decrease of homovanillic
acid in the CSF is actually considered a biomarker for patients
with Parkinson’s disease (LeWitt, 2012). Even if monoamine
oxidase B is located at the mitochondrial outer membrane in
both neurons and glial cells, a large portion of extracellular
dihydroxylphenylacetic acid may derive from the metabolism of
intraneuronal dopamine pool (Meissner et al., 2003). Catechol-O-
methyl transferase, however, is located extraneuronally both in
glial cells and postsynaptic membranes (Elsworth and Roth,
1997). Consistent with the significant decrease in dopamine
transporter and tyrosine hydroxylase-positive terminals in the stri-
atum of c-rel/ mice, lower homovanillic acid levels probably
reflect a decrease in the amount of released dopamine, rather
than a decrease of newly synthesized dopamine in striatal ter-
minals. Indeed, the absence of dihydroxylphenylacetic acid
changes may even reflect increased dopamine synthesis in the
spared terminals to partially compensate for the loss of dopamine
striatal innervation, as seen in both asymptomatic and symptom-
atic Parkinson’s disease primate models (Pifl and Hornykiewicz,
2006).
These neurochemical changes were accompanied by the onset
of motor deficits. Impairments in locomotor and total motor ac-
tivity were evident in c-rel/ mice at 18 months of age, but not
in younger mice, as previously observed (O’Ryordan et al., 2006;
Ahn et al., 2008). The spontaneous locomotor activity was par-
ticularly affected, as aged c-rel/ mice travelled 70% less dis-
tance in 1 h. We also recorded motor activity for six consecutive
days using a video-based observation system in the PhenoTyper
cages, to avoid stress-related biases. In our setup conditions,
wild-type mice moved little during the first 4 days of habituation
and were more explorative after the fifth day of habituation. In
contrast, c-rel/ mice displayed constantly lower locomotor ac-
tivity. Although we cannot exclude that exploratory activity might
also be reduced from this test, additional gaiting analysis sup-
ported the presence of locomotor dysfunctions in 18-month-old
c-rel/ mice. Similarly to other Parkinson’s disease rat models
(Vlamings et al., 2007; Chuang et al., 2010; Vandeputte et al.,
2010), 18-month-old c-rel/ mice showed changes in several
gait-related parameters. They had a lower swing speed, i.e. the
speed at which the paw moves while in mid-air. In addition,
c-rel/ mice spent a longer time to reach the maximum contact
area of front limb paws with the glass. Notably, both swing
speed and max contact area were related to bradykinesia
(Koopmans et al., 2007) and were observed in rats with bilateral
(Vlamings et al., 2007) and unilateral (Chuang et al., 2010)
6-hydroxydopamine lesion. Static parameters were also affected
in c-rel/ mice, as the distance between controlateral footprints
of knockout animals increased compared to wild-type mice, indi-
cating a peculiar posture modification. Posture modifications, such
as widely spread hind toes, were previously reported in
MTPT-treated mouse models of Parkinson’s disease (Rozas
et al., 1998). Furthermore, forelimb print length was reduced in
c-rel/ mice suggesting that they had dysfunctional paw exten-
sions and coordination. All these changes might be related to
reduced paw pressure during paw contact, a phenomenon that
may be related to muscle tone rigidity and altered use of paw
surface, as suggested by Chuang et al. (2010).
c-Rel-deficient mice were found to model key relevant features
of Parkinson’s disease including responsiveness to L-DOPA, that is
diagnostic of Parkinson’s disease (Lees, 1986). Indeed, treatment
with L-DOPA plus benserazide, a peripheral aromatic amino acid
decarboxylase inhibitor, reversed the deficit in locomotor activity
of c-rel/ mice evaluated through measuring the distance tra-
velled in 1 h. Moreover, L-DOPA treatment significantly improved
all gait-related deficits in c-rel/ mice, with the exclusion of print
length which, however, tended to recover.
Further pathological examination of aged c-rel/ brains
showed marked immunoreactivity for -synuclein, which accumu-
lated in the spared dopaminergic neurons of the substantia nigra
pars compacta. These intracellular aggregates were stained
with thioflavin S, indicating the presence of fibrillary -synuclein.
The immunoblot analysis confirmed the accumulation of soluble
-synuclein in the mesencephalon of c-rel/ mice, but not in the
cortex, hippocampus, or striatum. Remarkably, we also detected
urea/SDS insoluble -synuclein in the mesencephalon of 18-
month-old c-rel/ mice. -Synuclein deposition is considered a
central pathological event for the onset and progression of
Parkinson’s disease (Braak et al., 2003; Uversky et al., 2007;
Bellucci et al., in press) as -synuclein gene mutations and multi-
plications are responsible for developing familial forms of
Parkinson’s disease with classical brain histopathology (Bekris
et al., 2010). Experimental evidence suggests that -synuclein
may induce neuronal degeneration via multiple mechanisms
(Uversky et al., 2007; Bellucci et al., in press), but whether
-synuclein aggregation is the primary cause or an epiphenom-
enon in the pathogenic process of Parkinson’s disease has yet to
be established.
The presence of neuroinflammatory markers, including activated
microglial and astrocytic cells, is another important neuropatho-
logical feature of Parkinson’s disease brain (Hirsch and Hunot
2009). Studies in experimental models of Parkinson’s disease sug-
gest that microglia activation and up-regulation of inflammatory
mediators can both be induced by -synuclein and may contribute
to the pathogenesis of the disease (Zhang et al., 2005). Studies
examining astrocyte response in the substantia nigra pars com-
pacta of patients with Parkinson’s disease showed variable results
(Forno et al., 1992; Damier et al., 1993; Mirza et al., 2000; Song
et al., 2009) and the role of astrocytes in Parkinson’s disease ini-
tiation and progress is debated (Hirsch and Hunot 2009; Chung
et al., 2010). We observed a marked microglia activation in the
substantia nigra pars compacta and striatum but no GFAP-positive
astrocytic reaction in 18-month-old c-rel/ mouse brains. This
may either reflect an early stage of neuroinflammation in the
brain of c-rel/ mice or an effect associated with the lack of
c-Rel-mediated transcription, which needs to be investigated.
A remarkable increase in iron content, together with lower
physiological iron scavenger ferritin, is also present in the
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substantia nigra pars compacta of patients with Parkinson’s disease
(Sian-Hu¨lsmann et al., 2010). The cerebral iron accumulation has
been associated with local enhancement of the Fenton reaction
generating reactive oxygen species and -synuclein fibril formation
(Uversky et al., 2007; Sian-Hu¨lsmann et al., 2010). In mice treated
with MPTP, iron increases were correlated with the selective de-
generation of substantia nigra pars compacta dopaminergic neu-
rons (Lv et al., 2011). Moreover, recent studies reported increases
of iron and DMT1 in glia and neuromelanin-positive neurons of
patients with Parkinson’s disease and demonstrated a link between
DMT1 up-regulation and substantia nigra pars compacta degen-
eration in animal models of Parkinson’s disease (Salazar et al.,
2008; Lv et al., 2011). Consistently with their ability to develop
a Parkinson’s disease-like phenotype, 18-month-old c-rel/ mice
displayed increased amounts of both the 60 and 90 kDa forms of
DMT1 in the mesencephalon and striatum, in conjunction with
increased iron staining in the substantia nigra pars compacta.
Understanding the pathogenesis of Parkinson’s disease-like
neurodegeneration in aged c-rel/ mice needs further detailed
investigation. Emerging evidence indicates that the selective vul-
nerability of substantia nigra pars compacta neurons in Parkinson’s
disease depends on the peculiar ‘energy-demanding’ physiology of
these cells (Surmeier et al., 2011). Substantia nigra pars compacta
dopaminergic neurons display an enormous axonal field and a
number of synapses for each axon that is orders of magnitude
higher than that of other neurons (Arbuthnott and Wickens
2007). Moreover, during their pacemaking activity, substantia
nigra pars compacta dopaminergic neurons generate autonomous
action potentials by unusual engaging of L-type Ca2 + channels
that require subsequent activation of ATP-dependent Ca2 +
pumps to maintain proper cytoplasmic Ca2 + homeostasis
(Wilson and Callaway, 2000). Notably, Ca2 + -dependent pacemak-
ing and secondary generation of oxidative stress were observed in
substantia nigra pars compacta dopaminergic cells, but not in ven-
tral tegmental area neurons resistant to Parkinson’s disease
(Guzman et al., 2010). To afford the conspicuous energy
demand, mitochondria and endoplasmic reticulum in substantia
nigra pars compacta dopaminergic neurons generate amounts of
reactive oxygen species which are constantly neutralized by anti-
oxidant systems including super oxide dismutases (MnSOD and
copper and zinc SOD), catalases, and the glutathione peroxidase
(Halliwell, 2006). Activation of UCP4 and UCP5, the brain-specific
isoforms of UCP, also contribute to reducing the reactive oxygen
species generation and reactive oxygen species-mediated toxicity
(Kwok et al., 2010; Ho et al., in press). Interestingly, knocking-out
DJ1 (PARK7), a gene associated with an early-onset form of
Parkinson’s disease, downregulated the expression of UCP4 and
UCP5 and increased the oxidation of matrix proteins in substantia
nigra pars compacta dopaminergic neurons, but not in the ventral
tegmental area (Gutzman et al., 2010). All this evidence suggests
that sensitizing genetic backgrounds and environmental challenges
could easily synergize with the intrinsic stress of substantia nigra
pars compacta dopaminergic neurons to exacerbate cellular
damage, ageing, and ultimately death (Surmeier et al., 2011).
Notably, c-Rel factor is a transcriptional inducer of UCP4 (Ho
et al., in press), MnSOD (Bernard et al., 2001; Pizzi et al., 2005)
and anti-apoptotic Bcl-xL (Chen et al., 2000; Sarnico et al., 2009).
It can be hypothesized that reduced expression of UCP4 and
MnSOD in c-Rel-deficient mice might enhance reactive oxygen
species accumulation occurring with ageing in substantia nigra
pars compacta neurons (Cardozo-Pelaez et al., 1999). It is also
feasible that this oxidative stress may contribute to elevate intra-
cellular levels of -synuclein (Uversky et al., 2007), DMT1 and
iron (Salazar et al., 2008) and, in turn, may lead to -synuclein
aggregation (Uversky et al., 2007), microglia activation and neur-
onal damage (Zhang et al., 2005). Reduced Bcl-xL expression, by
lessening the resilience of substantia nigra pars compacta dopa-
minergic neurons to the vicious cycle of oxidative stressors and
-synuclein aggregation, would finally hasten cell death and the
development of motor deficits. A comprehensive evaluation of
mitochondrial function and transcriptional profiles in substantia
nigra pars compacta dopaminergic neurons of c-rel/ mice
could provide a validation of this hypothesis.
In conclusion, our data reveal a role for c-Rel factor as a regu-
lator of substantia nigra pars compacta susceptibility to ageing.
The specific pathology and loss of nigral dopaminergic neurons
in aged c-rel/ mice highlights the implications of c-Rel as a
potential genetic risk factor for Parkinson’s disease and a suitable
molecular target for drug discovery.
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